FASAY and thereafter NGS have shown that CLL patients often harbor minor clones expressing pathogenic TP53 variants (VAF 1%–5%) that progress during the course of disease [12, 22, 36, 37]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.